Birch Pollen Allergy - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 40
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BAC18BF9B94EN
Leaflet:

Download PDF Leaflet

Birch Pollen Allergy - Pipeline Review, H2 2017
Birch Pollen Allergy - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Birch Pollen Allergy - Pipeline Review, H2 2017, provides an overview of the Birch Pollen Allergy (Immunology) pipeline landscape.

Birch pollen allergy is a reaction which occurs soon after exposure to pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes drugs belonging to class of antihistamines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Birch Pollen Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Birch Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 1 and 1 respectively.

Birch Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Birch Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Birch Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Birch Pollen Allergy (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Birch Pollen Allergy - Overview
Birch Pollen Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Birch Pollen Allergy - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
Birch Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergy Therapeutics Plc
Anergis SA
Biomay AG
HAL Allergy BV
Laboratorios LETI SL
Birch Pollen Allergy - Drug Profiles
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AllerT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Tree - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Birch Pollen Allergy - Dormant Projects
Birch Pollen Allergy - Discontinued Products
Birch Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study
Feb 08, 2017: Anergis Completes Patient Recruitment In Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT
Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016
May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy
May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis
Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria
Jun 04, 2015: Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015
Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial
Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Birch Pollen Allergy, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2017
Birch Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2017
Birch Pollen Allergy - Pipeline by Anergis SA, H2 2017
Birch Pollen Allergy - Pipeline by Biomay AG, H2 2017
Birch Pollen Allergy - Pipeline by HAL Allergy BV, H2 2017
Birch Pollen Allergy - Pipeline by Laboratorios LETI SL, H2 2017
Birch Pollen Allergy - Dormant Projects, H2 2017
Birch Pollen Allergy - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Birch Pollen Allergy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Grass Pollen Allergy - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 43 pages

Ask Your Question

Birch Pollen Allergy - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: